| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K03911514 | CTRPv2 | pan-cancer | AAC | 0.093 | 0.07 |
| mRNA | BAY 61-3606 | GDSC1000 | pan-cancer | AAC | 0.061 | 0.07 |
| mRNA | BRD-K61166597 | CTRPv2 | pan-cancer | AAC | 0.057 | 0.07 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.062 | 0.07 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | 0.063 | 0.07 |
| mRNA | PFI-1 | GDSC1000 | pan-cancer | AAC | 0.058 | 0.07 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.07 |
| mRNA | docetaxel:tanespimycin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.057 | 0.08 |
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | -0.055 | 0.08 |
| mRNA | NVP-BEZ235 | CTRPv2 | pan-cancer | AAC | 0.072 | 0.08 |